{"title":"Pembrolizumab治疗tmb -高、msi -高去势抵抗性前列腺癌","authors":"Satoshi Muraoka, Hisanobu Tosuji, Yuya Iwahashi, Hiroki Kawabata, Ryusuke Deguchi, Takahito Wakamiya, Shimpei Yamashita, Yasuo Kohjimoto, Isao Hara","doi":"10.1002/iju5.70062","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The use of pembrolizumab in patients with microsatellite instability-high (MSI-high) and tumor mutation burden-high (TMB-high) prostate cancer in Japan is not widely reported. Here, we report the case of a patient with MSI-high and TMB-high prostate cancer who responded well to pembrolizumab after multiple systemic treatments.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 68-year-old Japanese man was diagnosed with cT4N1M1a prostate cancer. He was treated with several androgen receptor signaling inhibitors and chemotherapy. After intense systemic treatment, disease progression was confirmed, and genomic testing detected MSI-high and TMB-high. However, treatment with pembrolizumab resulted in marked prostate-specific antigen reduction and significant shrinkage of metastases.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Genomic tests should be considered for high-grade tumors. MSI-high and TMB-high prostate cancer responded well to pembrolizumab in this case, but patients should be carefully monitored for the development of side effects after administration of pembrolizumab.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 5","pages":"449-453"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70062","citationCount":"0","resultStr":"{\"title\":\"TMB-High, MSI-High Castration-Resistant Prostate Cancer Treated With Pembrolizumab\",\"authors\":\"Satoshi Muraoka, Hisanobu Tosuji, Yuya Iwahashi, Hiroki Kawabata, Ryusuke Deguchi, Takahito Wakamiya, Shimpei Yamashita, Yasuo Kohjimoto, Isao Hara\",\"doi\":\"10.1002/iju5.70062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>The use of pembrolizumab in patients with microsatellite instability-high (MSI-high) and tumor mutation burden-high (TMB-high) prostate cancer in Japan is not widely reported. Here, we report the case of a patient with MSI-high and TMB-high prostate cancer who responded well to pembrolizumab after multiple systemic treatments.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case Presentation</h3>\\n \\n <p>A 68-year-old Japanese man was diagnosed with cT4N1M1a prostate cancer. He was treated with several androgen receptor signaling inhibitors and chemotherapy. After intense systemic treatment, disease progression was confirmed, and genomic testing detected MSI-high and TMB-high. However, treatment with pembrolizumab resulted in marked prostate-specific antigen reduction and significant shrinkage of metastases.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Genomic tests should be considered for high-grade tumors. MSI-high and TMB-high prostate cancer responded well to pembrolizumab in this case, but patients should be carefully monitored for the development of side effects after administration of pembrolizumab.</p>\\n </section>\\n </div>\",\"PeriodicalId\":52909,\"journal\":{\"name\":\"IJU Case Reports\",\"volume\":\"8 5\",\"pages\":\"449-453\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70062\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJU Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70062\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
TMB-High, MSI-High Castration-Resistant Prostate Cancer Treated With Pembrolizumab
Introduction
The use of pembrolizumab in patients with microsatellite instability-high (MSI-high) and tumor mutation burden-high (TMB-high) prostate cancer in Japan is not widely reported. Here, we report the case of a patient with MSI-high and TMB-high prostate cancer who responded well to pembrolizumab after multiple systemic treatments.
Case Presentation
A 68-year-old Japanese man was diagnosed with cT4N1M1a prostate cancer. He was treated with several androgen receptor signaling inhibitors and chemotherapy. After intense systemic treatment, disease progression was confirmed, and genomic testing detected MSI-high and TMB-high. However, treatment with pembrolizumab resulted in marked prostate-specific antigen reduction and significant shrinkage of metastases.
Conclusion
Genomic tests should be considered for high-grade tumors. MSI-high and TMB-high prostate cancer responded well to pembrolizumab in this case, but patients should be carefully monitored for the development of side effects after administration of pembrolizumab.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
